We have previously reported that vitamin K2 (VK2) but not VK1 has a potent apoptosis-inducing effect on freshly isolated leukemia cells from patients with various types of leukemia. By multi-color flow cytometric analysis using monoclonal antibody (mAb), APO2.7, which detects mitochondrial 7A6 antigen specifically expressed by cells undergoing apoptosis, we further investigated the apoptosis-inducing effect of VK2 on minor populations of leukemic blast cells in bone marrow from patients with myelodysplastic syndrome ( 
Introduction
Myelodysplastic syndrome (MDS) is caused by a clonal hematopoietic stem cell disorder and often progresses to overt myeloid leukemia (post-MDS AML). The prognosis of post-MDS AML is poor, with a median survival time of less than 12 months. 1, 2 If patients with these disorders receive intensive chemotherapy, approximately 50-60% will achieve complete remission, but the median remission duration is less than 8 months despite maintenance chemotherapy. 1, 3 Since most MDS patients are elderly, their bone marrow cannot tolerate intensive chemotherapy. Only young patients can be treated successfully by allogeneic bone marrow transplantation, if a histocompatible donor is available. 4 Therefore, establishment of new therapy for elderly patients with post-MDS AML appears to be an important issue.
Vitamin K (VK) is a generic term for compounds that include phytonadione (VK1), the menaquinone series (VK2) and menadione (VK3). The natural types of vitamin K, VK1 and VK2, are well known to act as cofactors for ␥-carboxylation of selected glutamates at the N-terminals of prothrombin and other VK-dependent coagulation factors. As shown in Figure 1 , the congeners of VK share a common chemical structure consisting of a naphthoquinone nucleus with various side chains. VK1 has a long phytol side chain, whereas VK2 has an unsaturated side chain composed of 4-13 isoprene units (polyprenylalcohol). It has previously been reported that these congeners have some growth inhibitory effect on tumor cell lines including hepatoma cells such as Hep3B and Hep40, although the mechanism of growth inhibition is not well understood. [5] [6] [7] [8] In addition, we have reported that VK2 showed potent apoptosis induction on primary cultured leukemia cells. This effect was more prominent on transformed leukemia cells as compared with that on CD33-or CD3-positive normal bone marrow cells. 9 In the present study, we established a new method of flow cytometry for detecting the minor population of cells undergoing apoptosis using the monoclonal antibody (mAb) APO2.7, which targets the 38 kDa mitochondrial membrane protein (7A6 antigen) expressed by apoptotic cells. 10 Using this method, we examined whether VK2 shows a specific cytocidal effect on transformed blastic cells from MDS patients in vitro. Our results suggest that VK2 may be useful for treating elderly patients with MDS in blastic transformation.
Materials and methods

Reagents
Menaquinone 3 (MK3), MK4, MK5 and phytonadione (VK1) were all synthesized and supplied by Eisai Chemical (Tokyo, Japan) ( Figure 1) .
Cell lines and patients
Jurkat cells were a gift from Dr Shigeo Koyasu (Department of Immunology and Microbiology, School of Medicine, Keio University, Japan). A human B lymphoma cell line, CTB-1, was established in our laboratory. 11 In contrast to Jurkat cells, this cell line was resistant to apoptosis induced by treatment with an anti-Fas mAb, CH-11.
11 Bone marrow samples were obtained from 15 MDS patients, including one patient with refractory anemia (RA), three with refractory anemia with excess of blasts (RAEB), four with RAEB in transformation (RAEB-T), and seven with post-MDS AML, after they had given informed consent. The diagnosis of MDS was based on the French-American-British (FAB) classification. Freshly isolated bone marrow mononuclear cells were incubated with RPMI 1640 supplemented with 10% FBS in the presence or absence of either VK2 or VK1 for 3-5 days, and then the cells were processed for flow cytometry. Fluorescein isothiocyanate (FITC)-conjugated mouse anti-human CD33, CD34, CD13, CD14, and CD3 mAbs and phycoerythrin (PE)-conjugated anti-human CD33, CD34, CD45, and CD20 mAbs were also obtained from Immunotech. Immunofluorescence was analyzed by flow cytometry using an EPICS XL2 flow cytometer (Coulter Japan, Tokyo, Japan).
Cell surface antigen analysis
Detection of DNA fragments
DNA fragments were detected by in situ end-labeling. We used the ApopTag kit-Fluorescein (Oncor, Gaithersburg, MD, USA) according to the manufacturer's protocol. 12 For detecting DNA laddering, the extracted DNA was separated by 2% agarose gel electrophoresis and the gels were stained with SYBR Green I.
Results
VK2 selectively eliminates blastic cells from the bone marrow cells of MDS patients
We have previously reported that VK2, but not VK1, induced apoptosis of leukemia cells in vitro. 9 As shown in Figure 
Flow cytometric detection of apoptotic cells using monoclonal antibody APO2.7
A novel monoclonal antibody, APO2.7 was raised against the 38 kDa mitochondrial membrane protein 7A6 antigen. 10 Since 7A6 antigen is selectively expressed on the mitochondrial membrane in cells undergoing apoptosis, we attempted to detect apoptotic cells using this mAb after VK2 treatment of bone marrow mononuclear cells. First, we examined the sensitivity of detecting apoptotic cells by flow cytometry. Treatment of Jurkat and CTB-1 cells with anti-Fas mAb (CH-11) for 12 h resulted in the typical morphological features of apoptosis in Jurkat cells, but not in CTB-1 cells, a cell line which shows resistance against Fas-mediated apoptosis 11 (data not shown). In situ end-labeling using an ApopTag kit demonstrated DNA fragmentation in CH-11-treated Jurkat cells, but not in CTB-1 cells, as we previously reported 
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− 'Jurkat gate' even though apoptotic Jurkat cells were diluted to 5% in the CTB-1 cell suspension. As shown in Figure 5b , the percentage of APO2.7-positive cells in the 5% Jurkat cell suspension was almost identical to that in the 100% Jurkat cell suspension. These data suggest that, when at least 5% of cells are undergoing apoptosis, it is detectable by flow cytometry using APO2.7 mAb. Using this method, we next investigated whether VK2 selectively induced apoptosis in the blast cells of MDS patients. 
VK2 specifically induces apoptosis of blasttransformed cells in MDS
As shown in Figure 6 
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++ gated area, which represents mature myeloid cells, less prominent enhancement of APO2.7-positive cells was detected as compared with culture in control medium. Not shown is that MKs showed almost no effect on CD3-positive cells in MDS patients. These data suggest the selective apoptosis-inducing activity of VK2 towards leukemic blast cells of MDS patients in vitro. Table 1 summarizes the percentages of APO2.7-positive cells in the leukemic blast gates of all 15 MDS patients tested. VK2 significantly enhanced APO2.7 expression by all leukemic blast cells as compared with cells treated with the control medium, although the efficacy of APO2.7 induction varied (some cells were sensitive to VK2 and some were not so sensitive), as observed in our previous report regarding various types of acute leukemias. 9 However, a relatively high percentage of APO2.7-positive cells in the controls (cases 1, 5, 8, 13 and 15) suggested a high incidence of spontaneous apoptosis of MDS cells in vitro.
Discussion
In the present study, we demonstrated that VK2 selectively induced in vitro apoptosis of immature transformed blast cells from MDS patients by multicolor flow cytometric analysis using a new mAb, APO2.7. Regarding detection of apoptotic cells using antibodies, nonspecific binding-related plasma membrane damage during the process of apoptosis should be considered. APO2.7 has been reported to be superior to other methods, including annexin V, for flow cytometric detection of apoptotic cells because of its lower nonspecific binding. 13 In this study, positive APO2.7 was assessed after gating, so that detection was focused on cells relatively early in the process of apoptosis. Cells in the late stage of apoptosis become shrunken and thus were gated out from the flow cytogram. Accordingly, apoptosis assessed by this method only reflects cells in the early stage of the process. However, this method clearly demonstrated that the cytocidal effect of VK2 on the minor population of leukemia cells in MDS patients is mediated through an apoptotic process.
As shown in Figure 6 , exposure to MKs resulted in downmodulation of CD34 on leukemia cells, probably because of damage to the plasma membrane during the process of apoptosis. However, in contrast to CD34, the expression of CD33 was slightly enhanced. Therefore, decreased CD34 expression by leukemia cells may also be partly related to dif- ferentiation. A differentiation-inducing activity of VK2 has been reported in HL-60 and U937 cells.
14 Because leukemia cells were identified as the CD34
− population and the myeloid gate was established as the CD34
−
/CD33
+ area (Figure 7) , the efficacy of induction of apoptosis by VK2 appeared to be underestimated for leukemia cells and overestimated for mature myeloid cells because of contamination of the myeloid gate by leukemia cells losing CD34 expression.
So far, we do not know the effect of VK2s on CD34-positive normal clones, because most of the leukemic cells tested in this study were CD34-positive. In addition, CD34-positive cells account for about 1% of bone marrow mononuclear Whole bone marrow mononuclear cells were treated with 3-10 M of MKs for 3-5 days. Then, the percentage of APO2.7-positive cells in the leukemic blast gate was assessed by flow cytometry, as described in Figure 6 .
cells. Although selective elimination of the leukemic clone by VK2 was suggested in Figure 2 , further study of the effect of VK2 on normal enriched CD34 cells will be the next step. The data shown in this report suggest that VK2 could be used for treating patients with MDS in blastic transformation. In addition, our flow cytometric method for monitoring a small population of apoptotic cells may be useful for investigating the pathogenesis of various hematological disorders which are supposed to involve ineffective hematopoiesis such as MDS. manuscript. We also thank Ayako Hirota for her excellent technical assistance. MY and KM contributed equally to this report and should be regarded as co-first authors. This study was supported by a Grant-in-Aid for Science Research (C) from the Ministry of Education, Science and Culture of Japan to KM.
